Peripheral Biomarkers for Alzheimer's Disease: Update and Progress.
作者信息
Sabbagh Marwan N, Blennow Kaj
机构信息
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
出版信息
Neurol Ther. 2019 Dec;8(Suppl 2):33-36. doi: 10.1007/s40120-019-00171-6. Epub 2019 Dec 12.
Abstract
摘要
相似文献
1
Peripheral Biomarkers for Alzheimer's Disease: Update and Progress.阿尔茨海默病的外周生物标志物：更新与进展
Neurol Ther. 2019 Dec;8(Suppl 2):33-36. doi: 10.1007/s40120-019-00171-6. Epub 2019 Dec 12.
2
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架：迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
3
Progress update: fluid and imaging biomarkers in Alzheimer's disease.进展更新：阿尔茨海默病中的流体和成像生物标志物
Biol Psychiatry. 2014 Apr 1;75(7):520-6. doi: 10.1016/j.biopsych.2013.07.031. Epub 2013 Sep 5.
4
[Application guidelines and research progress of biomarkers for Alzheimer's disease].[阿尔茨海默病生物标志物的应用指南与研究进展]
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Mar 6;56(3):262-269. doi: 10.3760/cma.j.cn112150-20210916-00902.
5
Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.阿尔茨海默病和帕金森病中的脑脊液生物标志物——从病理生理学到临床实践
Mov Disord. 2016 Jun;31(6):836-47. doi: 10.1002/mds.26656. Epub 2016 May 4.
6
Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease.外周血单核细胞中中性脂质的积累是阿尔茨海默病患者和有患病风险的无症状受试者的一个显著特征。
BMC Med. 2009 Nov 2;7:66. doi: 10.1186/1741-7015-7-66.
7
Recent Progress in the Pharmacotherapy of Alzheimer's Disease.阿尔茨海默病药物治疗的最新进展
Drugs Aging. 2017 Nov;34(11):811-820. doi: 10.1007/s40266-017-0499-x.
8
Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease.痴呆的病因和模式：在重新定义阿尔茨海默病的时代的更新。
Annu Rev Public Health. 2019 Apr 1;40:65-84. doi: 10.1146/annurev-publhealth-040218-043758. Epub 2019 Jan 14.
9
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease.2014 年美国国家阿尔茨海默病行动计划里程碑报告
Alzheimers Dement. 2014 Oct;10(5 Suppl):S430-52. doi: 10.1016/j.jalz.2014.08.103.
10
Molecular biomarkers of Alzheimer's disease: progress and prospects.阿尔茨海默病的分子生物标志物：进展与展望。
Dis Model Mech. 2018 May 8;11(5):dmm031781. doi: 10.1242/dmm.031781.
引用本文的文献
1
Inflammatory Markers and their Relationship with Cognitive Function in Alzheimer's Disease and Mild Cognitive Impairment. Systematic Review and Meta-Analysis.炎症标志物及其与阿尔茨海默病和轻度认知障碍中认知功能的关系。系统评价与荟萃分析。
Neuromolecular Med. 2025 Jul 25;27(1):53. doi: 10.1007/s12017-025-08866-w.
2
Virtual Reality and Serious Videogame-Based Instruments for Assessing Spatial Navigation in Alzheimer's Disease: A Systematic Review of Psychometric Properties.用于评估阿尔茨海默病空间导航能力的虚拟现实和基于严肃游戏的工具：心理测量特性的系统评价
Neuropsychol Rev. 2025 Mar;35(1):77-101. doi: 10.1007/s11065-024-09633-7. Epub 2024 Feb 26.
3
Discovery of Novel Markers for Identifying Cognitive Decline Using Neuron-Derived Exosomes.利用神经元衍生外泌体发现用于识别认知衰退的新型标志物
Front Aging Neurosci. 2021 Aug 26;13:696944. doi: 10.3389/fnagi.2021.696944. eCollection 2021.
4
An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease.一种改进的深度残差网络预测模型，用于阿尔茨海默病的早期诊断。
Sensors (Basel). 2021 Jun 18;21(12):4182. doi: 10.3390/s21124182.
5
Predicting Thioflavin Fluorescence of Retinal Amyloid Deposits Associated With Alzheimer's Disease from Their Polarimetric Properties.从偏振特性预测与阿尔茨海默病相关的视网膜淀粉样沉积物的硫黄素荧光
Transl Vis Sci Technol. 2020 Aug 14;9(2):47. doi: 10.1167/tvst.9.2.47. eCollection 2020 Aug.
本文引用的文献
1
Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment.在临床环境中实施血液中β-淀粉样蛋白和tau异构体定量之前需要考虑的关键步骤。
Neurol Ther. 2019 Dec;8(Suppl 2):129-145. doi: 10.1007/s40120-019-00166-3. Epub 2019 Dec 12.
2
A Review on MS-Based Blood Biomarkers for Alzheimer's Disease.基于质谱的阿尔茨海默病血液生物标志物综述
Neurol Ther. 2019 Dec;8(Suppl 2):113-127. doi: 10.1007/s40120-019-00165-4. Epub 2019 Dec 12.
3
Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology.血浆AD核心生物标志物开发进展：基于免疫磁珠还原的超导量子干涉装置技术的当前研究结果
Neurol Ther. 2019 Dec;8(Suppl 2):95-111. doi: 10.1007/s40120-019-00167-2. Epub 2019 Dec 12.
4
Salivary Biomarkers for Alzheimer's Disease and Related Disorders.用于阿尔茨海默病及相关疾病的唾液生物标志物
Neurol Ther. 2019 Dec;8(Suppl 2):83-94. doi: 10.1007/s40120-019-00168-1. Epub 2019 Dec 12.
5
An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform.使用单分子阵列（SiMoA）平台对阿尔茨海默病血液标志物的最新研究进展
Neurol Ther. 2019 Dec;8(Suppl 2):73-82. doi: 10.1007/s40120-019-00164-5. Epub 2019 Dec 12.
6
Reflections on the Utility of the Retina as a Biomarker for Alzheimer's Disease: A Literature Review.关于视网膜作为阿尔茨海默病生物标志物的效用的思考：文献综述
Neurol Ther. 2019 Dec;8(Suppl 2):57-72. doi: 10.1007/s40120-019-00173-4. Epub 2019 Dec 12.
7
Neurophysiological Markers of Alzheimer's Disease: Quantitative EEG Approach.阿尔茨海默病的神经生理学标志物：定量脑电图方法。
Neurol Ther. 2019 Dec;8(Suppl 2):37-55. doi: 10.1007/s40120-019-00169-0. Epub 2019 Dec 12.
8
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.淀粉样蛋白正电子发射断层扫描与轻度认知障碍或痴呆的医疗保险受益人的临床管理变化的相关性。
JAMA. 2019 Apr 2;321(13):1286-1294. doi: 10.1001/jama.2019.2000.
9
Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings.唾液中β淀粉样蛋白水平可检测，且能区分阿尔茨海默病痴呆患者与正常对照：初步研究结果。
BMC Neurol. 2018 Sep 26;18(1):155. doi: 10.1186/s12883-018-1160-y.
10
High performance plasma amyloid-β biomarkers for Alzheimer's disease.用于阿尔茨海默病的高性能血浆淀粉样蛋白-β生物标志物。
Nature. 2018 Feb 8;554(7691):249-254. doi: 10.1038/nature25456. Epub 2018 Jan 31.
Zotero 插件